You Think It’s a Switch, Until It Isn’t: The Brand-vs-Brand Drug-Switching Confusion Questions
There are two kinds of confusion in drug switching: the harmless kind, where the active ingredient is the same; and […]
General
Off-Label Prescribing Is Market Validation. It’s Also a $1.6 Billion Governance Problem.
In March 2025, a federal judge in New Jersey ordered a Johnson & Johnson subsidiary to pay more than $1.6
The OTC/Prescription Double-Dip: How People Accidentally Take the Same Drug Twice (And Why It’s Not Just “Missing the Label”)
Every so often, the pharmacy call that makes you wince isn’t for a rare reaction or a mysterious lab result.
The Brand-Generic Confusion Playbook: 40 Questions People Ask Before They Switch
If you’ve ever stared at a prescription that says one name and a pharmacy label that gives you another, you’re
AI Monitoring for Pharmacovigilance: How Drug Companies Track Mentions Before Regulators Do
The standard pharmacovigilance process has a timing problem Adverse events travel faster than case reports. A patient posts about a
Agentic AI Comes to Drug Safety: What Veeva’s AI Agents Mean for Pharmacovigilance Teams
The Short Answer Veeva Systems is running two parallel agentic AI programs in drug safety at once, and they are
FDA and EMA Have No AI-Generated Drug Content Rule. Here’s What Already Governs It
A compliance primer for Medical Affairs, Regulatory Affairs, Pharmacovigilance, and Brand teams The Short Answer Neither FDA nor EMA has
The Competitive Landscape for AI Search Visibility in Pharma: Who’s Actually Building What
Real Chemistry billed HealthGEO, launched on August 21, 2025, as the industry’s first healthcare-specific generative engine optimization (GEO) intelligence platform
If a Large Share of Prescriptions Are Off-Label, Your Forecast Has a Blind Spot
By 2002, an estimated 94% of gabapentin prescriptions were written for conditions the drug was never approved to treat [6].
Your Competitors Are Already Tracking AI Drug Mentions—Are You?
In May 2026, 5W AI Communications ran more than 60 patient and consumer prompts against ChatGPT, Claude, Perplexity, Gemini, and
The 20 Drug Brands AI Talks About Most — And Where Its Answers Diverge From the Record
The short answer: Twenty brand and generic names dominate AI-monitoring query volume tracked across consumer and clinical assistants: Lipitor, Advil,
Off-Label Drug Sales Demand Looks Like Growth. Until It Doesn’t.
In January 2026, Hims & Hers launched a compounded oral semaglutide pill priced at $49 for the first month. Nine
